太阳集团5493||欢迎登录

Be the most trusted biotech company

2019-08-20

Monoclonal Antibody HLX10 in Patients with Metastatic MSI-H/dMMR Solid Tumors
2019-08-14

First Patient Dosed in Global Phase 3 Clinical Trial of HLX10 in Combination with Chemotherapy in Patients with Metastatic Squamous NSCLC
2019-08-02

Henlius Innovative Anti-c-MET Monoclonal Antibody HLX55 Received IND Application Acceptance Notification from NMPA
2019-07-31

Henlius Innovative Anti-HER2 Monoclonal Antibody HLX22 Have Dosed First Patient for Its Phase 1 Study
2019-07-12

Henlius Novel Anti-PD-1 Antibody HLX10 Received Clinical Trial Approval in Taiwan for the Treatment of Hepatitis B
2019-07-04

Henlius Has Completed the Phase 3 Study of Its Adalimumab Injection HLX03
2019-06-21

EMA Accepted First “China-Developed” Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
2019-06-17

Henlius Presented Data of Two Anti-inflammatory Candidates at EULAR 2019
2019-06-10

Henlius Attends BIO 2019

1
2
3
4